

FDA approves first drug for rare form of rickets

April 23 2018



(HealthDay)—Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-

twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

A clinical trial found that 94 percent of adults who took Crysvida once a month achieved normal phosphorus levels, compared with 8 percent of those who took a placebo, according to the FDA. In children, 94 to 100 percent of those treated with Crysvida every two weeks achieved normal phosphorus levels.

The most common negative side effects of Crysvida in adults were back pain, headache, [restless leg syndrome](#), decreased vitamin D, dizziness, and constipation. The most common [negative side effects](#) in children were headache, injection site reaction, vomiting, decreased vitamin D, and fever, the FDA said.

"XLH differs from other forms of rickets in that vitamin D therapy is not effective," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in an agency news release. "This is the first FDA-approved medication for the treatment of XLH and a real breakthrough for those living with this serious disease."

More information: [More Information](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: FDA approves first drug for rare form of rickets (2018, April 23) retrieved 7 January 2024 from <https://medicalxpress.com/news/2018-04-fda-drug-rare-rickets.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is

provided for information purposes only.